Past, present and future of drug conjugates for cancer therapy

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Nature Cancer

• Publication date

  2025-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/s43018-025-01042-wPMID 40935909
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

  2024influential reference
• Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide

  2024cited by this paper
• Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors

  2024cited by this paper
• Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.

  2024cited by this paper
• Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials

  2024cited by this paper
• TOPOLOGY: A phase II study to evaluate the efficacy and toxicities of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

  2024cited by this paper
• Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot

  2024cited by this paper
• Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance

  2024cited by this paper
• Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate

  2024cited by this paper
• Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

  2024influential reference
• [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.

  2024cited by this paper
• First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

  2024cited by this paper
• Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel Antibody-Drug Conjugates.

  2024cited by this paper
• Rational Identification of Novel Antibody‐Drug Conjugate with High Bystander Killing Effect against Heterogeneous Tumors

  2024cited by this paper
• Could a Long-Acting Prodrug of SN-38 be Efficacious in Sacituzumab Govitecan-Resistant Tumors?

  2024cited by this paper
• The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results

  2024cited by this paper
• Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: a systematic review and meta-analysis.

  2023cited by this paper
• Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

  2023cited by this paper
• A DNA-encoded chemical library based on chiral 4-amino-proline enables stereospecific isozyme-selective protein recognition

  2023cited by this paper
• A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule-Drug, Antibody-Drug, and Peptide-Drug Conjugates.

  2023cited by this paper
• TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).

  2023cited by this paper
• Rise of Antibody-Drug Conjugates: The Present and Future.

  2023cited by this paper
• Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

  2023influential reference
• Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

  2023cited by this paper
• Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

  2022influential reference
• Antibody drug conjugate: the “biological missile” for targeted cancer therapy

  2022cited by this paper
• Selective tumor targeting enabled by picomolar fibroblast activation protein inhibitors isolated from a DNA-encoded affinity maturation library

  2022cited by this paper
• Fibroblast Activation Protein triggers release of drug payload from non-internalizing small molecule-drug conjugates in solid tumors.

  2022influential reference
• [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

  2022cited by this paper
• A pH-responsive crosslinker platform for antibody-drug conjugate (ADC) targeting delivery.

  2022cited by this paper
• Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

  2022cited by this paper
• Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

  2022cited by this paper
• Designing antibodies as therapeutics.

  2022cited by this paper
• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

  2022cited by this paper
• CD22low/Bcl-2high expression identifies poor response to inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia

  2022cited by this paper
• First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

  2021cited by this paper
• Quantitative mass spectrometry imaging of drugs and metabolites: a multiplatform comparison

  2021cited by this paper
• Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

  2021cited by this paper
• Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

  2021cited by this paper
• Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA

  2021cited by this paper
• Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?

  2021cited by this paper
• Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results

  2021cited by this paper
• Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.

  2021cited by this paper
• An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications

  2021cited by this paper
• Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

  2021cited by this paper
• FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer

  2020cited by this paper
• Radiopharmaceutical therapy in cancer: clinical advances and challenges

  2020cited by this paper
• Analysis and modeling of cancer drug responses using cell cycle phase-specific rate effects

  2020cited by this paper
• Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

  2020influential reference
• Analytical Methods for the Detection and Quantification of ADCs in Biological Matrices

  2020cited by this paper
• The role of fibroblast activation protein in health and malignancy

  2020cited by this paper
• Ribosomal Synthesis of Backbone-Cyclic Peptides Compatible with In Vitro Display.

  2019cited by this paper
• A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors.

  2019cited by this paper
• Impressive response of CD30‐negative, treatment‐refractory mycosis fungoides to brentuximab vedotin

  2019cited by this paper
• A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.

  2019cited by this paper
• Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells

  2019cited by this paper
• Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

  2019cited by this paper
• Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody–Drug Conjugates

  2019cited by this paper
• Mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-resistant ovarian cancer: Final findings from the FORWARD II study.

  2019cited by this paper
• Cleavable linkers in antibody-drug conjugates.

  2019cited by this paper
• Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates

  2019cited by this paper
• Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability

  2019cited by this paper
• Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

  2019cited by this paper
• Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.

  2018influential reference
• Antibody-Drug Conjugates for Cancer Treatment.

  2018cited by this paper
• Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice

  2018cited by this paper
• Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.

  2017cited by this paper
• Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control

  2017influential reference
• Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

  2017cited by this paper
• Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.

  2017cited by this paper
• Gemtuzumab ozogamicin for acute myeloid leukemia.

  2017influential reference
• Development of Efficient Chemistry to Generate Site-Specific Disulfide-Linked Protein- and Peptide-Payload Conjugates: Application to THIOMAB Antibody-Drug Conjugates.

  2017cited by this paper
• Ligand-Targeted Drug Delivery.

  2017cited by this paper
• Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

  2017cited by this paper
• Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.

  2017cited by this paper
• Targeted Delivery of Cytotoxic Drugs: Challenges, Opportunities and New Developments.

  2017influential reference
• Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

  2017cited by this paper
• Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains

  2017cited by this paper
• Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?

  2017influential reference
• Mechanisms of Resistance to Antibody–Drug Conjugates

  2016cited by this paper
• Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design

  2016cited by this paper
• Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Antibody Drug Conjugates for Cancer Therapy

  2016cited by this paper
• DeBouganin Diabody Fusion Protein Overcomes Drug Resistance to ADCs Comprised of Anti-Microtubule Agents

  2016cited by this paper
• Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

  2016cited by this paper
• Principles in the design of ligand-targeted cancer therapeutics and imaging agents

  2015influential reference
• Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors

  2015cited by this paper
• Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer

  2014cited by this paper
• Antibody-drug conjugates: an emerging concept in cancer therapy.

  2014cited by this paper
• Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo

  2013cited by this paper
• Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study

  2013cited by this paper
• Linker technologies for antibody-drug conjugates.

  2013influential reference
• Toward Prediction of Efficacy of Chemotherapy: A Proof of Concept Study in Lung Cancer Patients Using [11C]docetaxel and Positron Emission Tomography

  2012cited by this paper
• Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.

  2012influential reference
• Protease-Activated Drug Development

  2012cited by this paper
• A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

  2011influential reference
• Introduction to current and future protein therapeutics: a protein engineering perspective.

  2011cited by this paper
• Effects of Anti-VEGF on Predicted Antibody Biodistribution: Roles of Vascular Volume, Interstitial Volume, and Blood Flow

  2011cited by this paper
• Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients

  2010cited by this paper
• Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention

  2010cited by this paper

• Emergent phase architectures in 2D materials for multimodal cancer therapy

  2026cites this paper
• Plant-Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors.

  2026cites this paper
• Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood-Brain Barrier.

  2026cites this paper
• Activatable near-infrared fluorescent probes for targeting the tumor microenvironment in cancer theranostics

  2026cites this paper
• Dual-payload small-molecule drug conjugates enable bystander anticancer activity with reduced nonspecific release.

  2026cites this paper
• L19-Conjugated Gold Nanoparticles for the Specific Targeting of EDB-Containing Fibronectin in Neuroblastoma

  2025cites this paper
• Snake venom-derived peptides as anticancer candidates: Pioneering next-generation therapies.

  2025cites this paper